Sugi Predict

Sugi Predict / Compounds / SCHEMBL22836735

SCHEMBL22836735

SCHEMBL22836735

CN[C@H]1CC[C@@H](CNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 16/20 0.66
▸ CRBN Q96SW2 16/20 0.66
▸ IKZF3 Q9UKT9 2/20 0.56
▸ TNF P01375 1/20 0.56
▸ IL1B P01584 1/20 0.56
▸ TBXA2R P21731 1/20 0.56
▸ IKZF1 Q13422 1/20 0.56
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC2 Q92769 1/20 0.53
▸ STAT3 P40763 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ CHRM2 P08172 1/20 0.53
▸ OPRM1 P35372 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21997777 1.00 DDB1 (0.66) DDB1CRBNIKZF3TNFIL1B
SCHEMBL21997775 1.00 DDB1 (0.66) DDB1CRBNIKZF3TNFIL1B
SCHEMBL29502361 1.00 DDB1 (0.66) DDB1CRBNIKZF3TNFIL1B
SCHEMBL1963795 0.93 DDB1 (0.75) DDB1CRBNIKZF3TNFIL1B
SCHEMBL23672431 0.91 DDB1 (0.64) DDB1CRBNIKZF3TNFIL1B
SCHEMBL23568155 0.91 DDB1 (0.64) DDB1CRBNIKZF3TNFIL1B
SCHEMBL23696180 0.91 DDB1 (0.64) DDB1CRBNIKZF3TNFIL1B
SCHEMBL21998089 0.90 DDB1 (0.61) DDB1CRBNIKZF3TNFIL1B
SCHEMBL22849385 0.90 DDB1 (0.61) DDB1CRBNIKZF3TNFIL1B
SCHEMBL29502479 0.90 DDB1 (0.61) DDB1CRBNIKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-12539295-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-03 — — US disclosed
US-20240131016-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-04-25 — — US disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 — — US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 — — US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 — — US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 — — US disclosed
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-11 — — US disclosed
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-11 — — US disclosed
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-02 — — US disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 — — EP disclosed
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-07-29 — — US disclosed
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-07-29 — — US disclosed
WO-2021127190-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 — — WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 DDB1 511/4885CRBN 39/4885IKZF3 202/4885
US-12539295-B2 IRAK degraders and uses thereof IRAK2, IRAK4, IRAK3 DDB1 2951/4885CRBN 70/4885IKZF3 252/4885
US-20240131016-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF IRAK4, IRAK2, IRAK3 DDB1 68/4885CRBN 322/4885IKZF3 266/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885
US-11779578-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885
US-11707457-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IKZF3 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.